Details About the Toxicity ScreenĪside from screening for constituents that are therapeutically active, researchers in Numinus’ labs have also created a toxicity screen for psychedelic mushrooms including both hepatotoxic and nephrotoxic compounds.
The company is actively working with regulators in an attempt to develop the tools necessary to establish a foundation that includes the proven scientific methods necessary for psychedelic products used in the mainstream. The tests were validated at Numinus’ labs in an effort to prove its psychedelics are safe and effective for use in treating depression as well as other mental health issues. The company’s screening for Psilocybe mushrooms constituents encompasses Psilocybin, Tryptophan, Norbaeocystin, Psilocin, Aeruginascin and more. Numinus’ lab has proactively validated its methods for identifying active constituents in the hopes of advancing the push for the legal use of psychedelics to treat mental health pathologies. Testing extends to the analysis of residues and contaminants. Psilocybe mushroom fruiting bodies, derivatives and other forms of the psychedelic are an example of the many matrices that methodologies are being developed for. Numinus has quickly evolved into an industry leader in the context of analytical testing methods for psychedelics. The hope is that these proprietary methods will serves as the evidence necessary to advance the discussions, setting the stage for Numinus to capture market share as quickly as possible. The tests will also be used to advance discussions with regulators who control access to the healthcare market. Numinus, a pioneer in the psychedelics mental healthcare space, recently announced its proprietary method for the screening of psychedelic mushrooms. The test, developed and also validated at Numinus’ own labs, will serve as a vital component of its upcoming services for third-party clients. This analytical testing is poised to take the company’s research and development to new heights, potentially catalyzing revenue through its ever-expanding pool of third-party clients. Numinus Wellness Inc. ( CVE: NUMI), has developed a proprietary form of testing for potency and toxicity scans.
0 kommentar(er)
